QIAN Xian, CHENG Dan, CHEN Anni, ZHANG Guoqing, ZHAN Qi. Analysis on rational application of esomeprazole for injection in hepatobiliary perioperative period[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 557-560. doi: 10.3969/j.issn.1006-0111.2018.06.018
| Citation:
|
QIAN Xian, CHENG Dan, CHEN Anni, ZHANG Guoqing, ZHAN Qi. Analysis on rational application of esomeprazole for injection in hepatobiliary perioperative period[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 557-560. doi: 10.3969/j.issn.1006-0111.2018.06.018
|
Analysis on rational application of esomeprazole for injection in hepatobiliary perioperative period
- Received Date: 2018-02-11
- Rev Recd Date:
2018-07-13
-
Abstract
Objective To investigate the rationality of esomeprazole for injection in hepatobiliary perioperative period of Eastern Hepatobiliary hospital (hereinafter referred to as our hospital), and to provide reference for the rational drug use in hepatobiliary perioperative. Methods By retrospective investigation, information of 300 randomly patients was collected from Jan to Sep in 2017 with esomeprezole for injection through consulting the electronic medical records, doctor's advice, inspection, etc. Of the 300 cases of medical records with esomeprazole for injection, the use frequency of esomeprazole were 416, statistical analysis was conducted in terms of the administration time, treatment course, usage and dosage, solvent, and the risk of stress ulcer. Results The rational rate of the administration time was 15.67%(47/300), the treatment course was 10.67%(32/300),the usage was 75%(312/416),dosage and solvent were 100%(416/416),and the ratio of patients with SU risk factors was 3.33%(10/300). Conclusion The rational application of esomeprezole in our hospital still need to be improved. The clinical pharmacists should strengthen clinical medicine education to improve rational drug use in our hospital.
-
References
|
[1]
|
KUPIEC TC, ALOUMANIS V, BEN M, et al. Physical and chemical stability of esomeprazole sodium solutions[J]. Ann Pharmacother, 2008,42(9):1247-1251. |
|
[2]
|
吕小娟, 艾伟鹏, 马林. 质子泵抑制剂预防危重症患者并发应激性溃疡的循证药物经济学评价[J].中国医院药学杂志,2015,35(24):2237-2240. |
|
[3]
|
UCHIYAMA T, HIGURASHI T, KURIYAMA H, et al. Oral esomeprazole vs injectable omeprazole for the prevention of hemorrhage after endoscopic submucosal dissection[J]. World J Gastrointest Endosc, 2017,9(10):514-520. |
|
[4]
|
KAGAMI T, YAMADE M, SUZUKI T, et al. Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype[J]. Clin Pharmacol Ther, 2018,103(5):906-913. |
|
[5]
|
黄瑾, 刘正跃, 田泾. 长期大剂量使用质子泵抑制剂的严重不良反应和药学监护[J].中国医院药学杂志,2012,32(20):1648-1651. |
|
[6]
|
VIDELA R, SOMMARDAHL CS, ELLIOTT SB, et al. Effects of intravenously administered esomeprazole sodium on gastric juice pH in adult female horses[J]. J Vet Intern Med, 2011,25(3):558-562. |
|
[7]
|
芦小燕, 戴幼琴, 陈维, 等. 基于循证的静脉用质子泵抑制剂预防应激性溃疡的合理性评价标准的建立[J].中国现代应用药学,2015,32(12):1481-1484. |
|
[8]
|
吴明杰. 住院患者注射用质子泵抑制剂不合理应用分析[J].中国医院用药评价与分析,2016,16(02):257-259. |
|
[9]
|
MEI J, YU Y, MA J, et al. Evaluation of the effectiveness of esomeprazole treatment strategies in the management of patients with gastroesophageal reflux disease symptoms:a meta-analysis[J]. Pharmazie, 2016,71(5):285-291. |
|
[10]
|
ZHOU J, QUINLAN M, GLENN K, et al. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers[J]. Br J Clin Pharmacol, 2016,82(4):1022-1029. |
|
[11]
|
孙敏, 黄坤明, 司继刚. 临床使用质子泵抑制剂的药学监护[J].河北医药,2016,38(02):275-278. |
|
[12]
|
张石革. 质子泵抑制剂临床应用的药学监护[J].中国执业药师,2015,12(07):31-37. |
-
-
Proportional views
-
DownLoad: